secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001628280-24-036163
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Q2 revenue $28.3M (-3% YoY), net loss $7.1M; raises FY24 revenue guidance to $99-101M
--------------------------------------------------------------------------------

- Q2 total revenue $28.3M (-3% YoY, +6% seq); Cell Processing $18.0M (+11% seq).
- GAAP net loss from cont. ops $7.1M (incl $4.1M iVexSol write-off) vs $5.5M loss YoY; adj net loss $2.3M.
- GAAP gross margin 51% vs 35% YoY; non-GAAP adj gross margin 52% vs 45%.
- Adjusted EBITDA $4.8M (17% rev) vs $1.7M (6%) YoY.
- Raises FY2024 revenue guidance to $99-101M from $95.5-100M; Cell Processing to $70-71M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828024036163/0001628280-24-036163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828024036163/blfs-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-036163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer